New CEO Vas Narasimhan wants to cut Novartis' R&D costs by using digital tech – and with this in mind the firm has scaled up a project involving virtual clinical trials. The Swiss pharma company ...

Novartis’ head of drug development Vas Narasimhan talks about the company’s stake in CAR-T immunotherapy. These cell therapies are set to transform treatment of blood cancers – but questions ...

Silas Zindel—13PHOTO/Redux Early in Vas Narasimhan’s career as a physician scientist, he worked on programs for treating HIV/AIDS in Africa and saw the impact of medicine in places that need ...

Narasimhan pointed to 13 blockbuster medicines in the company’s portfolio, including eight brands with peak sales potential of at least $3 billion. One of those, the anti-inflammatory drug ...

CEO Vas Narasimhan highlighted Novartis' strong performance in Q4 2024, with sales increasing 16% and core operating income ...

CNBC’s Angelica Peebles and Novartis CEO Vas Narasimhan join 'Squawk Box' to discuss the company's drug pipeline, managing patent cliffs, drug pricing under Trump, and more. US Ally Upgrades ...

CEO Vas Narasimhan, M.D., told investors. Kicking off the Swiss company’s annual Meet Novartis Management event in London Thursday morning, Narasimhan said he “wanted to say a word about our R ...

Vas Narasimhan, the CEO of Novartis, discusses the Swiss pharmaceutical company's first-quarter earnings. MAGA divided as Trump turns on Putin 'Trash' found deep inside a Mexican cave turns out to ...

"Even in this I think complex geopolitical environment, we feel confident we can deliver now this upgraded guidance," CEO Vas Narasimhan told CNBC's "Squawk Box Europe" on Tuesday. Sales continued ...

ZURICH, Nov 2 (Reuters) - Novartis (NOVN.S), opens new tab expects to increase its annual sales by least 5% per year in the coming years, CEO Vas Narasimhan said in an interview on Saturday ...

May 8, 2025 – Today, TIME reveals the second annual TIME100 Health list recognizing the 100 most influential individuals in health.

Chief Executive Vas Narasimhan said on Monday. U.S. President Donald Trump last month flagged potential import duties of about 25% on pharmaceuticals as part of measures affecting a range of ...